Cancer Diagnostics Market Forecast Report Outlines Size, Share, And Growth Opportunities Through 2030
What Growth Rate And Market Size Expansion Are Predicted For The Cancer Diagnostics Market Across The Forecast Period?
The cancer diagnostics market size has grown rapidly in recent years. It will grow from $25.5 billion in 2025 to $28.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising global cancer prevalence, increased investments in oncology research, expansion of hospital diagnostic infrastructure, growing adoption of imaging-based cancer detection, improvements in laboratory automation.
The cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $44.69 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising adoption of next-generation sequencing diagnostics, expansion of population-wide cancer screening programs, growing investments in AI-enabled oncology diagnostics, continuous innovation in multi-cancer detection tests. Major trends in the forecast period include increasing adoption of molecular and companion diagnostics, rising integration of ai in cancer detection, growing use of biomarker-based testing, expansion of high-throughput diagnostic platforms, enhanced focus on early cancer screening.
Claim Your Free Report Sample Today:
Which Underlying Drivers Are Influencing The Rapid Growth Of The Cancer Diagnostics Market?
The rising healthcare expenditure is expected to propel the growth of the cancer diagnostics market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances cancer diagnostics by supporting the adoption of advanced screening technologies and expanding access to early detection services. It improves diagnostic accuracy through greater investment in modern equipment and specialized labs, enabling timely intervention and better patient outcomes. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the cancer diagnostics market.
What Segmentation Areas Represent Major Opportunities For Expansion In The Cancer Diagnostics Market?
The cancer diagnostics market covered in this report is segmented –
1) By Products: Companion Diagnostics, Molecular Diagnostics
2) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging
3) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications
4) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users
Subsegments:
1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics,
2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics
What Key Market Trends Are Contributing To The Ongoing Development Of The Cancer Diagnostics Market?
Major companies operating in the cancer diagnostic device market are focusing on the development of technology with artificial intelligence (AI), such as QAi Prostate, to gain a competitive edge in the market. QAi Prostate is used as a cancer diagnostic device for prostate cancer diagnosis. For Instance, in March 2023, Qritive, a Singapore-based company that develops AI-powered diagnostic tools for pathologists, launched QAi Prostate. QAi Prostate is an advanced artificial intelligence (AI)-powered prostate cancer diagnosis tool. QAi Prostate uses machine learning algorithms to accurately identify and classify malignant and benign areas in prostate tissue samples. This tool is designed to help pathologists detect prostate cancer and differentiate between malignant and benign areas in prostate tissue samples.
Which Leading Players Have A Strong Presence In The Cancer Diagnostics Market?
Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics
Get Your In-Depth Cancer Diagnostics Market Report Now:
Which Parts Of The World Are Emerging As High-Potential Markets For The Cancer Diagnostics Market?
North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment